An associate in the Litigation Department, Peter Sandel focuses his practice on patent litigation matters. Mr. Sandel has been extensively involved in all aspects of patent litigation including trials in federal district courts and appeals to the United States Court of Appeals for the Federal Circuit. He has litigated patents is a wide variety of technical areas with a particular emphasis on biotechnology and pharmaceuticals. Mr. Sandel has also litigated patents regarding internet technologies, semiconductors and medical devices.

Representative Cases

• Glaxo Group Limited v. Genentech, Inc., 2:10-cv-02764 (C.D. Cal.): representing Genentech in patent infringement case involving monoclonal antibody technology.
• Biogen Idec Inc. v. Bayer Healthcare Pharmaceuticals, EMD Serono, Inc., Pfizer Inc., and Novartis Pharmaceuticals Corp., 2:10-cv-02734 (D. N.J.): representing Biogen in patent infringement case regarding treatments for multiple sclerosis.
• Life Technologies, Inc. et al. v. Illumina Inc. and Solexa Inc., 3:11 cv 703 (S.D. Cal.): representing Life Technologies in patent infringement case regarding next-gen sequencing instruments sold by both Illumina and Life Technologies.
• Paid Search Engine Tools LLC. v. Yahoo! Inc., Google Inc. and Microsoft Corp., 07-cv-403 (E.D. Tex.): defended Yahoo! against claims of patent infringement; claims invalidated on summary judgment, currently on appeal to Federal Circuit.
• Merck Sharp & Dohme Pharmaceuticals SRL v. Teva Pharmaceuticals, Inc., 07-cv-1596 (D. N.J.): successfully prevented Teva from launching generic version of Singulair™, Merck’s top selling product, after five-day trial.
• MedImmune LLC v. PDL Biopharma Inc., 08-cv-5590 (N.D. Cal.): represented PDL in DJ case brought by MedImmune in which MedImmune sought declaration of invalidity and non-infringement and PDL asserted counterclaims of breach of contract and patent infringement.
• PDL Biopharma Inc. v. Alexion Pharmaceuticals Inc., 07-cv-156 (D. Del.): represented PDL in patent infringement action regarding Alexion’s product, Soliris™.
• Yeda Research and Development Co. Ltd. v. Imclone Systems Inc. and Aventis Pharmaceuticals, Inc., 03-cv-8484 (S.D. N.Y.): successfully challenged ownership of patent related to Erbitux. After bench trial, Court awarded patent ownership to Yeda.
• Israel Bio-Engineering Project v. Amgen, Inc. et al., 02-cv-6860 (C.D. Cal.): defended against allegations regarding ownership of patent, case resolved on summary judgment in Yeda’s favor.